Physician profile
Nancy Dooley
NPI 1215381702
$2,644.29
in general payments reported to CMS, 2019-2025
18 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $494 · 2023: $393 · 2024: $284 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026 · Education: $21.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.22 |
| Education | $21.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $498.63 | 2021-2025 | Farxiga, Lynparza |
| Amgen INC. | $294.06 | 2023-2025 | Tavneos, Parsabiv, Krystexxa |
| Calliditas Therapeutics US INC. | $269.56 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $265.56 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $203.30 | 2022-2025 | |
| Lilly USA, LLC | $188.85 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $169.36 | 2025 | Ozempic, Wegovy |
| Travere Therapeutics, INC. | $167.10 | 2024-2025 | Filspari |
| Vifor Pharma, INC. | $129.26 | 2022 | |
| Aurinia Pharma U.S., INC. | $106.30 | 2023-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $101.95 | 2025 | |
| Fresenius USA Marketing, INC. | $69.85 | 2022-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $40.91 | 2022-2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $40.35 | 2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $36.76 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.41 | 2024 | Jardiance |
| Apellis Pharmaceuticals, INC. | $22.88 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $14.20 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Dooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.